Copy to clipboard 
restor3d successfully completed capital-raising efforts totaling $38 million, bringing their total raised to $188 million to date. The latest funding rounds included participation from existing and new private investors, including Summers Value Partners.
The investments will fuel the company’s continued growth and the launch of four 3D-printed product lines in 2025 and 2026, including:
- Veritas Reverse Total Shoulder: Introducing a single tray instrument system making patient-specific implants accessible to a wider shoulder patient population. The patient-specific baseplate allows surgeons to optimize both the joint center of rotation and fixation. Both glenoid and humeral implants feature TIDAL Technologyfor enhanced bone integration. Pending FDA 510(k) clearance.
- iTotal Identity 3DP Porous Cementless Total Knee: The first fully cementless, patient-specific knee system, designed for optimal coverage and precise alignment while eliminating intraoperative guesswork. FDA 510(k) clearance received last week.
- Kinos Modular Stem Total Ankle: A cutting-edge total ankle system optimized for delivery through an anterior approach, providing enhanced surgical flexibility and personalized fit. FDA 510(k) clearance received late last year.
- Velora 3DP Porous Acetabular System: A next-generation porous hip cup designed to promote osseointegration by incorporating TIDAL Technology and long-term stability in hip arthroplasty. Pending FDA 510(k) clearance.
Kurt Jacobus, CEO and Co-Founder of restor3d, said, “This funding allows us to further scale our technology, expand access to truly personalized care, and continue setting new standards in orthopedic treatment. We are redefining what’s possible in orthopedics to better serve our surgeons and patients.”
Source: restor3d, Inc.
restor3d successfully completed capital-raising efforts totaling $38 million, bringing their total raised to $188 million to date. The latest funding rounds included participation from existing and new private investors, including Summers Value Partners.
The investments will fuel the company’s continued growth and the launch of four 3D-printed...
restor3d successfully completed capital-raising efforts totaling $38 million, bringing their total raised to $188 million to date. The latest funding rounds included participation from existing and new private investors, including Summers Value Partners.
The investments will fuel the company’s continued growth and the launch of four 3D-printed product lines in 2025 and 2026, including:
- Veritas Reverse Total Shoulder: Introducing a single tray instrument system making patient-specific implants accessible to a wider shoulder patient population. The patient-specific baseplate allows surgeons to optimize both the joint center of rotation and fixation. Both glenoid and humeral implants feature TIDAL Technologyfor enhanced bone integration. Pending FDA 510(k) clearance.
- iTotal Identity 3DP Porous Cementless Total Knee: The first fully cementless, patient-specific knee system, designed for optimal coverage and precise alignment while eliminating intraoperative guesswork. FDA 510(k) clearance received last week.
- Kinos Modular Stem Total Ankle: A cutting-edge total ankle system optimized for delivery through an anterior approach, providing enhanced surgical flexibility and personalized fit. FDA 510(k) clearance received late last year.
- Velora 3DP Porous Acetabular System: A next-generation porous hip cup designed to promote osseointegration by incorporating TIDAL Technology and long-term stability in hip arthroplasty. Pending FDA 510(k) clearance.
Kurt Jacobus, CEO and Co-Founder of restor3d, said, “This funding allows us to further scale our technology, expand access to truly personalized care, and continue setting new standards in orthopedic treatment. We are redefining what’s possible in orthopedics to better serve our surgeons and patients.”
Source: restor3d, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
